Yatra Online to Launch IPO at Rs 135-142 per Share
Yatra Online, a leading travel technology startup, has set a price band of Rs 135-142 per share for its initial public offering (IPO). The IPO will open for subscription on September 15 and close on September 20.
The company plans to raise Rs 602 crore via fresh issue and an offer for sale (OFS) of up to 12.18 million shares from its promoters and existing shareholders. On the upper end of the price band, the total issue size comes at Rs 775 crore.
The company will use the net proceeds from the fresh issue to fund strategic investments, acquisitions, and inorganic growth, as well as customer acquisition and retention, technology, and other organic growth initiatives.
Yatra Online is India’s largest corporate travel services provider in terms of the number of corporate clients and the third largest online travel company in India among key OTA (online travel agency) players in terms of gross booking revenue and operating revenue. It has the largest number of hotel and accommodation tie-ups among key domestic OTA players.
The IPO is being managed by SBI Capital Markets, DAM Capital Advisors, and IIFL Securities. Link Intime India is the registrar.
The company’s shares are expected to list on the BSE and NSE on September 29.
Here are some key details of the IPO:
- Price band: Rs 135-142 per share
- Issue size: Rs 775 crore
- Fresh issue: Rs 602 crore
- OFS: Up to 12.18 million shares
- Listing date: September 29
The IPO is expected to be well-received by investors, given Yatra Online’s strong growth prospects and dominant position in the Indian online travel market.
- 22 Sep
Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits
Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.
- 22 Sep
Signature Global IPO Subscribed 11.88 Times on Final Day
The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.
- 22 Sep
Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding
Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.
- 22 Sep
Pharma company Valiant Laboratories to go public on September 27
Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.
- 21 Sep
Unihealth Consultancy makes tepid debut on NSE Emerge
Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.